

## The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study

### SUPPLEMENTARY MATERIALS

Supplementary Table 1: Response to BRAF2 significantly correlated to the degree of response to BRAF1

		CR		PR		SD		MR		PD	
Response to BRAF1		7	12%	35	58%	12	20%	2	3%	4	7%
Response to BRAF2	CR	4	57%	1	3%	0	0%	0	0	0	0%
	PR	1	14%	9	26%	2	17%	0	0	0	0%
	SD	2	29%	11	31%	4	33%	0	0	0	0%
	MR	0	0%	5	14%	1	8%	2	100%	1	25%
	PD	0	0%	9	26%	5	42%	0	0	3	75%